Scott David Solomon, M.D.
This page shows the publications co-authored by Scott Solomon and E. Orav.
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med. 2021 10; 27(10):1818-1824.
Baseline Characteristics of the VANISH Cohort. Circ Heart Fail. 2019 12; 12(12):e006231.
The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial. Am Heart J. 2017 May; 187:145-155.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.